Fortis Healthcare Limited
Tower-A, Unitech Business Park, Block-F,
South City 1, Sector – 41, Gurgaon,
Haryana – 122 001 (India)

Tel	: 0124 492 1033
Fax	: 0124 492 1041
Emergency	: 105010
Email	: secretarial@fortishealthcare.com
Website	: www.fortishealthcare.com

FHL/SEC/2022-23 | February 10, 2023

The National Stock Exchange of India Ltd. **Scrip Symbol: FORTIS**	**BSE Limited** **Scrip Code:532843**

Sub: Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Madam / Sir,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. February 10, 2023, *inter-alia*, considered and approved the Standalone and Consolidated un-audited financial results of the Company for the quarter and period ended on December 31, 2022.

Accordingly, please find enclosed standalone and consolidated un-audited financial results along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended on December 31, 2022. Further, a copy of the press release and investor presentation being issued in this regard is also enclosed.

The meeting commenced at 1100 Hours IST and concluded at 1930 Hours IST.

This is for your information and record.

Thanking you,
Yours sincerely,
For **Fortis Healthcare Limited**

Murlee Manohar Jain
Company Secretary
ICSI Membership: F9598

Encl: a/a

B S R & Co. LLP

Chartered Accountants

Building No.10,12th Floor, Tower-C,
DLF Cyber City, Phase-II,
Gurugram – 122 002, India

Telephone: +91 124 719 1000
Fax: +91 124 235 8613

Limited Review Report on unaudited standalone financial results of Fortis Healthcare Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Fortis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Healthcare Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to following Notes in the Statement:

   a. Note 5 and 6 of the Statement which deal with various matters including the ongoing investigation by Serious Fraud Investigation Office ("SFIO") on Fortis Healthcare Limited and its subsidiaries ("the Group") regarding alleged improper transactions and non-compliances with laws and regulations including Companies Act, 2013 (including matters relating to remuneration paid to managerial personnel). These transactions and non-compliances relate to or originated prior to take over of control by reconstituted board of directors in the year ended 31 March 2018. As mentioned in the note, the Group has been submitting information required by SFIO and and is also cooperating in the regulatory investigations.

   As explained in the said note, the Group had recorded significant adjustments/ provisions in its books of account during the year ended 31 March 2018. The Company has launched legal proceedings and has also filed a complaint with the Economic Offences Wing ('EOW') against erstwhile promoters and their related entities based on the findings of the investigation conducted by the Group. Further, based on management's detailed analysis and consultation with external legal counsel, a further provision has been made and recognised in the year ended 31 March 2021 for any contingency that may arise from the aforesaid issues. As per the management, any further financial impact, to the extent it can be reliably estimated as at present, is not expected to be material.

ay

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office:
14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

b. Note 4 of the Statement relating to the order dated 22 September 2022 of the Hon'ble Supreme Court whereby it has directed the Hon'ble High Court of Delhi inter alia that it may also consider issuing appropriate process and appointing forensic auditor(s) to analyse the transactions entered into between the Company and RHT Health Trust and other related transactions. The above mentioned Note also states that the Hon'ble Supreme Court has observed that prima facie, it appears to be acquisition of proprietary interest of RHT Health Trust by the Company are to subserve the business structure of the Company.

Our conclusion is not modified in respect of the above matters.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rajesh Arora

Partner

Membership No.: 076124

UDIN:23076124BGZBHR5049

Gurugram

10 February 2023

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rupees in lacs)

Particulars	Standalone					
	Quarter ended			Nine months ended		Year ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	Unaudited	Unaudited	Unaudited	Una[illegible]	[illegible]	

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rupees in lacs)

Particulars	Quarter ended			Nine months ended		Year ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
a) Reversal of Impairment/(Impairment) of investment in Subsidiary Company	941	5,121	-	4,829	-	(1,628)
Net exceptional gain / (loss)	**941**	**5,121**	**-**	**4,829**	**-**	**(1,628)**

4. The Board of Directors, after seeking inputs from reputed investment bankers, had approved an equity infusion of Rupees 400,000 lacs at a price of Rupees 170 per equity share into the Company by Northern TK Venture Pte Ltd Singapore (NTK) ("Acquirer"), a wholly owned subsidiary of IHH Healthcare Berhad, Malaysia through a preferential allotment ("Preferential Issue"), subject to approval of the shareholders and other regulatory approvals which constituted 31.1% share capital of the Company. The shareholders of the Company approved the Preferential Issue by requisite majority at their Extra Ordinary General Meeting dated August 13, 2018. The Acquirer had received the approval from Competition Commission of India (CCI) on October 30, 2018 and the preferential allotment was made on November 13, 2018. Pursuant to the consummation of the same, Northern TK [illegible] Pte Ltd. had appointed 2/3 [illegible]

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

Pursuant to the Judgement, Hon'ble High Court of Delhi vide its order dated 18th October 2022 has directed Decree Holder to file an application defining contours of the forensic audit sought, which could thereafter be considered by the Delhi High Court. Decree holder has filed application(s) before Delhi High Court seeking appropriate directions in connection with forensic audit. Matter is pending adjudication and next date of hearing is 16th February, 2023.

... in view of the legal positions/claim(s) and defence(s) available to the Company and basis external legal advice, the management believes that it has a strong case on merits. It is of the view that these transactions were conducted in ... disclosures to public shareholders of the Company and to the regulatory authorities, in the requisite manner. Therefore, no ... in the unaudited standalone Financial Results.

... was filed by the Company before the Hon'ble Supreme Court of India, praying for grant of permission ...

... the aforesaid brand transition ...

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(i) The Company's Board of Directors initiated additional procedures/ enquiries of certain entities in the Group that were impacted in respect of the matters investigated by the external legal firm. Pending the additional procedures/ enquiries ("**Additional Procedures/ Enquiries**") and since the investigation was subject to the limitations on the information available to the external legal firm and their qualifications and disclaimers as described in their investigation report, as disclosed in the audited financial statements for the years ended March 31, 2018, March 31, 2019 and March 31, 2020 certain audit qualifications were made in respect of FHL's financial statements for those financial years, as the statutory auditors were unable to comment on the nature of those matters, the provisions established thereof, or any further potential impact on the financial statements. In order to resolve the same, the Board mandated the management to undertake review of certain areas in relation to historical transactions for the period April 1, 2014 to September 30, 2018 involving additional matters by engaging independent experts with specialized forensic skills to assist with the Additional Procedures/Enquiries and provide inputs and expert advice in connection therewith. The independent experts submitted their report which was discussed and considered by the Board in its meeting held on September 16, 2020.

(ii) The Board noted that the Additional Procedures/Enquiries, prima facie, revealed further instances of payments made to the erstwhile promoter or to their directly or indirectly related parties including erstwhile promoter group entities which were potentially improper However, all of the amounts identified in the Additional Procedures/Enquiries had been previously provided for or expensed in the financial statements of FHL or its subsidiaries. There are no other improper transactions identified by the Additional Procedures/Enquiries or the management, which had not been expensed or provided.

(iii) In connection with the potentially improper transactions, the Company has undertaken a detailed review of each case to assess the Company's legal rights and has initiated necessary action.

C. Key findings during the investigation by the external legal firm and during the Additional Procedures/Enquiries by independent experts

(i) Fortis Hospitals Limited (FHsL), a wholly owned subsidiary of the Company, had placed secured Short-Term Investments in the nature of Inter Corporate Deposits (ICDs) with three companies ('borrowers') aggregating to Rupees 49,414 lacs on July 1, 2017 for a term of 90 days. Further, FHsL received intimation that the borrowers became a part of the erstwhile Promoter Group with effect from December 15, 2017. These borrowers continued to be related parties until February 16, 2018. subsequent to which the shareholding of the erstwhile Promoter Group in the Company was reduced to 0.77%. In terms of agreements dated September 30, 2017, FHsL assigned the outstanding ICDs to a third party. Such assignment was subsequently terminated on January 5, 2018. On February 28, 2018, these ICDs were secured by way of a duly registered charge on the present and future assets of the Borrowers. ICDs aggregating to Rupees 44,503 lacs including interest accrued thereon of Rupees 4,260 lacs calculated up to March 31, 2018 remained

[illegible]

18. The amounts outstanding from the Lessor as on March 31, 2018 aggregated to Rupees 2,173 lacs. Additionally,

[illegible]

In view of the facts stated above and the uncertainty in the ultimate recovery of the aforesaid balances, the Company had recorded provisions aggregating to Rupees 4,743 lacs in the Standalone Financial Results for the year ended March 31, 2018.

SFIO has sought information in respect of this transaction and the same has been duly provided by the Company. Further, as stated above, a complaint has been filed with the EOW in November 2020 by the Company for certain other matters in which a reference has been made to such SFIO enquiries as well as to the Company's responses thereto and EOW is investigating the matter. A First Information Report (FIR) was registered by EOW in July 2021 against the above complaint.

(iii) FHsL, a wholly owned subsidiary of the Company, had advanced moneys to an entity towards acquisition of property in Mumbai in financial year 2013-14 which did not materialize. Of the total advance of Rupees 10,000 lacs, balance of Rupees 2,375 lacs was outstanding to be received back. Post-dated cheques received from the entity were dishonoured, and FHsL initiated legal proceedings in this regard. FHsL had accrued for the interest amounting to Rupees 174 lacs up to March 31, 2018 on the advance for the purpose of including the same in the legal claim on the entity. However, in line with applicable accounting norms, interest thereon for the period subsequent to March 31, 2018 was not accrued considering the uncertainties around ultimate realization ... months.

In view of the facts stated above and the uncertainty in the ultimate
recovery of the aforesaid balances, the Group had
recorded provisions aggregating to Rupees 2,549 lacs towards the amount
s due, including interest, in the year ended

FORTIS HEALTHCARE LIMITED

CIN: L85 [redacted]

observed in the earlier investigation that there were significant fluctuations in the NAV of the investments during a [illegible]. Further, in the internal correspondence within the Company, investments in the overseas funds [illegible] During year ended March 31, 2018, investments held in the [illegible] issued. Pursuant to this SEBI, vide order dated December 21, 2018, modified its previous order dated October 17, 2018 deleting FHsL from the list of entities against whom the Order was directed. Pursuant to this, the suspension order by National Securities Depository Limited for debits in beneficial owner account of FHsL was accordingly removed. Vide Order dated March 19, 2019, ("Confirmatary Order") SEBI confirmed the directions issued vide ad interim ex-parte order dated October 17, 2018 read with order dated December 21, 2018, till further orders. SEBI also directed the Company and FHsL to take all necessary steps to recover Rupees 40,300 lacs along with due

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

In the SCN-2, EHIRCL has been clubbed along with the other noticees, and has been painted with the same brush as the other notices in alleging that certain noticees, including EHIRCL, were part of a fraudulent and deceptive device wherein they acted in fraudulent manner which led to the misuse and/or diversion of funds from a listed company i.e. FHL, amounting to approximately Rupees 397.12 crore for the ultimate benefit of RHC Holdings and the erstwhile promoters. Thereby, it is alleg [illegible] ...s from the Company, [illegible] for the benefit of the promoter entities [illegible]

Further, the Board and the shareholders of the Company approved the merger of two wholly owned international subsidiaries of the company. This is subject to other regulatory approvals.

Date: February 10, 2023

Place: Gurugram

For and on behalf of the Board of Directors

Ashutosh

Dr. Ashutosh Raghuvanshi
Managing Director & CEO
DIN: 02775637

Fortis Healthcare Limited

B S R & Co. LLP

Chartered Accountants

Building No. 10, 12th Floor, Tower-C,
DLF Cyber City, Phase-II,
Gurugram – 122 002, India

Telephone: +91 124 719 1000
Fax: +91 124 235 8613

Limited Review Report on unaudited consolidated financial results of Fortis Healthcare Limited for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Fortis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Fortis Healthcare Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its associates and joint ventures for the quarter ended 31 December 2022 and year to date results for the period from 1 April 2022 to 31 December 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent:

(i) Fortis Healthcare Limited

Subsidiaries:

(i) Escorts Heart Institute and Research Centre Limited ("EHIRCL")

(ii) Fortis Hospitals Limited

(iii) Fortis Asia Healthcare Pte Limited

(iv) Fortis Healthcare International Limited

(v) Fortis Global Healthcare (Mauritius) Limited

(vi) Fortis Malar Hospitals Limited

(vii) Malar Stars Medicare Limited

(viii) Fortis Health Staff Limited

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office:
14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

(ix) Fortis Cancer Care Limited

(x) Fortis La Femme Limited

(xi) Fortis Health Management (East) Limited

(xii) Hiranandani Healthcare Private Limited

(xiii) SRL Limited

(xiv) SRL Diagnostics Private Limited

(xv) SRL Reach Limited

(xvi) SRL Diagnostics FZ- LLC

(xvii) Fortis Healthcare International Pte Limited ('FHIPL')

(xviii) Birdie and Birdie Realtors Private Limited

(xix) Stellant Capital Advisory Services Private Limited

(xx) RHT Health Trust Manager Pte Limited

(xxi) Fortis Emergency Services Limited

(xxii) Fortis Hospotel Limited

(xxiii) Escort Heart and Super Speciality Hospital Limited

(xxiv) International Hospital Limited

(xxv) Hospitalia Eastern Private Limited

(xxvi) Fortis Health Management Limited

(xxvii) Medical Management Company Limited

(xxviii) Mena Healthcare Investment Company Limited

(xxix) DDRC SRL Diagnostics Limited

Joint ventures:

(i) Fortis Cauvery

(ii) Fortis C- Doc Healthcare Limited

(iii) SRL Diagnostics (Nepal) Private Limited

Associates:

(i) Lanka Hospitals Corporate Plc

(ii) THR Infrastructure Pte Ltd

(iii) RHT Health Trust ('RHT')

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to the following Notes in the Statement:

   a. Note 5 and 6 of the Statement which deal with various matters including the ongoing investigation by Serious Fraud Investigation Office ("SFIO") on Fortis Healthcare Limited and its subsidiaries regarding alleged improper transactions and non-compliances with laws and regulations including Companies Act, 2013 (including matters relating to remuneration paid to managerial personnel). These transactions and non- compliances relate to or originated prior to take over of control by reconstituted board of directors in the year ended 31 March 2018. As mentioned in the note, the Group has been submitting information required by SFIO and is also cooperating in the regulatory investigations/ proceedings.

As explained in the said note, the Group had recorded significant adjustments/ provisions in its books of account during the year ended 31 March 2018. The Company has launched legal proceedings and has also filed a complaint with the Economic Offences Wing ('EOW') against erstwhile promoters and their related entities based on the findings of the investigation conducted by the Group. Further, based on management's detailed analysis and consultation with external legal counsel, a further provision has been made and recognised in the year ended 31 March 2021 for any contingency that may arise from the aforesaid issues. As per the management, any further financial impact, to the extent it can be reliably estimated as at present, is not expected to be material.

b. Note 10 of the Statement relating to the order dated 22 September 2022 of the Hon'ble Supreme Court whereby it has directed the Hon'ble High Court of Delhi inter alia that it may also consider issuing appropriate process and appointing forensic auditor(s) to analyse the transactions entered into between Fortis Healthcare Limited ('FHL') and RHT and other related transactions. The above mentioned Note also states that the Hon'ble Supreme Court has observed that prima facie, it appears to be acquisition of proprietary interest of RHT Health Trust by FHL are to subserve the business structure of FHL.

Our conclusion is not modified in respect of the above matters.

7. The Statement includes the interim financial information of sixteen Subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 642 lacs and Rs. 1,818 lacs, total net loss after tax (before consolidation adjustments) of Rs. 1,449 lacs and Rs. 2,922 lacs and total comprehensive income (before consolidation adjustments) of Rs. 1,448 lacs and Rs. 2,920 lacs, for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022 respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 261 lacs and Rs. 2,013 lacs and total comprehensive income of Rs. 261 lacs and Rs. 2,013 lacs, for the quarter ended 31 December 2022 and for the period from 1 April 2022 to 31 December 2022 respectively as considered in the Statement, in respect of three associates and three joint ventures, based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the Parent's management, these financial information are not material to the Group.

   Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rajesh Arora

Partner

Membership No.: 076124

UDIN:23076124BGZBHQ5778

Gurugram

10 February 2023

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rupees in lacs)

Particulars	Consolidated					
	Quarter Ended			Nine Months Ended		Year Ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Revenue from operations	155,988	160,720	146,665	465,493	433,951	571,761
2. Other income	1,170	1,553	669	4,793	2,135	2,734
3. Total income (1+2)	**157,158**	**162,273**	**147,334**	**470,286**	**436,086**	**574,495**
4. Expenses						
(a) Purchases of medical consumable and drugs	36,542	36,497	33,390	107,690	107,063	140,337
(b) Changes in inventories of medical consumable and drugs	(717)	(7)	(27)	(459)	(3,656)	(4,614)
(c) Employee benefits expense	26,268	26,810	25,110	78,605	73,506	97,294

FORTIS HEALTHCARE LIMITED

CIN: L85110PB1996PLC045933

Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS

FORTIS HEALTHCARE LIMITED

CIN: L85110PB1996PLC045933

Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rupees in lacs)

Particulars	Consolidated					
	Quarter Ended			Nine Months Ended		Year Ended
	December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Diluted earnings per share - In Rupees	-	-	-	-	-	-

FORTIS HEALTHCARE LIMITED

CIN: L85110PB1996PLC045933

Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rupees in lacs)

S.No	Particulars	Quarter ended			Nine Months Ended		Year Ended
		December 31, 2022	September 30, 2022	December 31, 2021	December 31, 2022	December 31, 2021	March 31, 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

4. Exceptional gain included in the above unaudited Consolidated Financial Results include:

(R[illegible] in lacs)

In order to overcome the above, additional procedures/ enquiries were initiated as below.

B. Additional procedures/enquiries by the reconstituted Board

(i) The Company's Board of Directors initiated additional procedures/ enquiries of certain entities in the Group that were impacted in respect of the matters investigated by the external legal firm. Pending the additional procedures/enquiries ("**Additional Procedures/ Enquiries**") and since the investigation was subject to the limitations on the information available to the external legal firm and their qualifications and disclaimers as described in their investigation report, as disclosed in the audited financial statements for the years ended March 31, 2018, March 31, 2019 and March 31, 2020 certain audit qualifications were made in respect of FHL's financial statements for those financial years, as the statutory auditors were unable to comment on the nature of those matters, the provisions established thereof, or any further potential impact on the financial statements. In order to resolve the same, the Board mandated the management to undertake review of certain areas in relation to historical transactions for the period April 1, 2014 to September 30, 2018 involving additional matters by engaging independent experts with specialized forensic skills to assist w[illegible]

Lessor for refund of the advance paid but the same were returned unpaid. Additionally, expenditure aggregating to Rupees 2,843 lacs was incurred towards capital work-in-progress on the premises proposed to be taken on lease from

Complaint has been filed in this regard, with the EOW in November 2020 against erstwhile promoters / erstwhile promoters group company and EOW is investigating the matter. A First Information Report (FIR) was registered by EOW in July 2021 against the above complaint.

(v) During the year ended March 31, 2018, the Company through its subsidiary (i.e. Fortis Hospitals Limited ("FHsL")), purchased further 51% equity interest in Fortis Emergency Services Limited (FESL) at an aggregate consideration of Rupees 0.255 lacs from erstwhile promoter group company. Subsequently, FHsL advanced a loan to FESL, which was used to repay the outstanding unsecured loan amount of Rupees 215 lacs to an erstwhile promoter group company. Certain documents suggest that the loan repayment by FESL and some other payments to the erstwhile promoter group company may have been ultimately routed through various intermediary companies and used for repayment of the ICDs /vendor advance to FHsL / Company. Further, FESL was not in a position to repay loan to the erstwhile promoter group company. FHsL also could not directly takeover the loan, as FHsL (holding 49%) could not have taken over the burden of the entire debt of FESL. Therefore, this transaction was in a way to help the erstwhile promoter group company(51% shareholders) to avoid making payment for its share, and place FHsL in a situation where it would find it hard to recover from its own now wholly owned subsidiary Further, the said loan advanced by FHsL to FESL was impaired in the books of account of FHsL due to anticipated chances of non-recovery.

Complaint has been filed with the EOW in November 2020 against erstwhile promoters / erstwhile promoters group company and EOW is investigating the matter. A First Information Report (FIR) was registered by EOW in July 2021 against the above complaint.

(vi) Remuneration to ex-chairman

The Company having considered all necessary facts and taking into account external legal advice, had on June 27, 2018 decided to treat as *non-est* the Letter of Appointment dated September 27, 2016, as amended, ("LoA") issued to the erstwhile Executive Chairman of the Company in relation to his role as 'Lead: Strategic Initiatives' in the Strategy Function. Since the LoA was treated as non-est, the Company received legal advice from its counsels that the amount paid under the aforesaid LoA (amounting to Rupees 1,768 lacs) appears to be an arrangement designed to circumvent the managerial remuneration limits under Section 197 of the Companies Act, 2013 read with relevant Central Government approvals and thus was wrongfully paid. Thus, as per the legal advice , the payments made to him under this LoA for the role of 'Lead: Strategic Initiatives' ought to be considered and characterized as payments which are in the nature of managerial remuneration, as regulated and governed in section 197 of the Companies Act, 2013. An amount of Rupees 234 lacs that was reimbursed in relation to expenses incurred was in excess of the amounts approved by the Central Government under Section 197 of the Companies Act, 2013. Accordingly, the Company sent a letter to the erstwhile Executive Chairman seeking refund of the excess amounts paid to him over and above the managerial remuneration limit, as specified under the Companies Act, 2013 read with the relevant government approvals in this regard. The erstwhile Executive Chairman sent a notice to the Company claiming Rupees 4,610 lacs as allegedly due to him under the employment agreement. The Company replied to the same through its legal counsel denying any liability and stated that the demand was not payable being illegal. Subsequently, Company filed a complaint against the erstwhile Executive Chairman before EOW. The Company has received back vehicles which were being used by him. However, IT assets and excess amounts paid are yet to be received.

In view of the above, the amounts paid to him under the aforesaid LoA and certain additional amounts reimbursed in relation to expenses incurred (in excess of the amounts approved by the Central Government under section 197 of the [illegible]

[illegible] hile Executive C
hairman before EOW on account of both of the above payments and EOW is investigating the [illegible]

excess remuneration paid from the company to erstwhile executive chairman of ~ Rupees 528 lacs was compensated through the foreign wholly owned subsidiary.

(b) Payments were made to an erstwhile promoter entity from another foreign wholly owned subsidiary of the Company under an investment advisory agreement amounting to equivalent ~ Rupees 344 lacs for the period June 2016 to September 2016. However, there was nothing on record to suggest that any services were rendered by the erstwhile promoter entity under this agreement.

(vii) During the financial year 2014-15, FHsL acquired 100% stake in Birdie & Birdie Realtors Pvt Ltd. ("Birdie") from certain persons related to the erstwhile promoters, wherein Rupees 12,275 lacs were paid towards ICDs at a rate of interest of 14% per annum and Rupees 7,725 lacs were paid for the shares acquired. The total enterprise value of Birdie was projected at Rupees 20,000 lacs based on the valuation report of land and building by an independent valuer. However, the equity valuation of Rupees 7,725 lacs was arrived based on a land and building valuation report by another valuer of Rupees 23,700 lacs and on assumption that the Land has to be sold in 6-8 months, which in reality did not happen. Also, the "subject property photographs" used in the mentioned two valuation reports were identical. Also, the ICD's of Rupees 12,275 lacs were utilized to repay/replace the then existing debts including that of erstwhile promoters and person/entities related/known to the erstwhile promoters. It is possible that the erstwhile promoters acted in order to make excess money to repay the loans availed by Birdie from them, persons related to them and entities related/known to them. Further, out of total goodwill generated on consolidation amounting to Rupees 10,661 lacs, goodwill to the extent of Rupees 9,430 lacs was impaired in earlier years to bring the investment value in line with the market value of the property.

There have been certain queries raised on this transaction by the SFIO. The Company has responded to the said queries. Further, in the above referred Complaint filed with the EOW in November 2020 against erstwhile promoters, SFIO enquiries and the Company's responses have been mentioned and EOW is investigating the matter. A First Information Report (FIR) was registered by EOW in July 2021 against the above complaint.

(viii) The Company through its overseas subsidiaries [i.e. Fortis Asia Healthcare Pte. Ltd, Singapore and Fortis Global Healthcare (Mauritius) Limited] made investments in Global Dynamic Opportunity Fund, an overseas fund. It was observed in the earlier investigation that there were significant fluctuations in the NAV of the investments during a short span of time. Further, in the internal correspondence within the Company, investments in the overseas funds have been referred to as related party transactions. During year ended March 31, 2018, investments held in the Global Dynamic Opportunity Fund were sold at a discount of 10%. As at March 31, 2018, the carrying value of the investments in the overseas fund were recorded at the net recoverable values based on subsequent realisation. The consequential foreseeable loss of Rupees 5,510 lacs (between the previously recorded carrying value of the investment and the amount subsequently realised) was considered in the Consolidated Financial Results for the year ended March 31, 2018.

There is no further finding in additional procedures/enquiries by independent experts on this matter. Further, the investigation by the external legal firm done also mentioned that it appeared that GDOF was not related to Fortis based on the procedures performed by them. Accordingly, no further action is being taken.

(ix) In respect of certain other matters found during the Additional Procedures/Enquiries by independent experts no actions [illegible] recommended since there were no sufficient evidences on those matters. However, there is no [illegible] the financials.

[illegible] D. Based on investigation carried out by the external legal firm and the additional procedures enquiries by independe[illegible] experts, all identified/required adjustments/provisions/disclosures [illegible] the company. The Company has also submitted findings of the investigation Report of the external legal firm and the additional procedures/enquiries by independent experts to the relevant regulatory authorities. Further, on relevant [illegible] Company has also filed a complaint with the EOW against the erstwhile promoters/erstwhile promoter group [illegible] companies and EOW is investigating the matter. Recovery /claim proceedings have also been initiated in the matters as recommended by the legal counsels. A First Information Report (FIR) was registered by EOW in July 2021 against the above complaint.

in the diversion of funds. A Show-Cause Notice (SCN-1) was issued by SEBI to various entities including the Company and FHsL on November 20, 2020. In the SCN-1, it was inter-alia alleged that the consolidated financials of the Company at the relevant period were untrue and misleading for the shareholders of the Company and the Company had circumvented certain provisions of the SEBI Act, Securities Contracts (Regulation) Act, 1956, and certain SEBI regulations. In response, a joint representation/reply was filed by the Company and FHsL on December 28, 2020 praying for quashing of the SCN-1 by inter alia reiterating that the Company and FHsL, were in fact victims of the schemes of the erstwhile Promoters (Malvinder Mohan Singh and Shivinder Mohan Singh) and justice, equity and fairness demands that the victim ought not be punished for the offences of the wrongdoers. All acts impugned in the SCN-1 relate to the period when the erstwhile Promoters controlled the affairs of Company and FHsL and the erstwhile Promoters are no longer involved in the affairs of the Company and FHsL. The erstwhile Promoters were responsible for financial misrepresentation and not the Company and FHsL. Post resignation of the erstwhile Promoters in February 2018, the Board of Directors of the Company, solely comprising independent Di[illegible]

[illegible] ...dia and SEBI which approved the open offer which was triggered by such pref[illegible]al allotment. Any [illegible]

[illegible] ...ole Member on January 20, 2021 and w[illegible] ...itten submissions were filed. SEBI passed an order dated April 19, 2022 [illegible] -1 and directed the Company & FHsL to purs[ue] the measures taken to recover the amount of Rupees 397.12 [illegible] crore (approx.) along with the interest from erstwhile [illegible] such measures and report the same to Board of Directors [illegible] ...ly monitor the progress of [illegible] regular intervals. Based on the aforesaid allegations [illegible] actions taken by the Company against the erstwhile promoters and related entities, SEBI imposed a penalty of Rs 100 lacs and Rs 50 lacs on Company and FHsL respectively. The Company and FHsL have filed an appeal against the order dated April 19, 2022 before Hon'ble Securities Appellate Tribunal Mumbai. On August 25, 2022, SEBI filed its affidavit in reply in the matter. Thereafter, the Company and FHsL have filed a rejoinder to SEBI's reply and the matter has been adjourned to February 21, 2023.

On April 09, 2021, SEBI issued another Show cause notice (SCN-2) to various noticees including Escorts Heart Institute and Research Centre Limited ("EHIRCL"). In the said SCN-2, with respect to EHIRCL, it has been alleged that Rupees 567 crore was lent by the Company to EHIRCL in 2011, which was subsequently transferred by EHIRCL to Lowe Infra and Wellness Private Limited ("Lowe") in multiple transactions fo[illegible] ...Lowe was then [illegible] ...s allegedly indirectly to be acquired by [illegible] Company through its subs[illegible] [illegible] ...on of funds was carried out to portray that the loan extended by the Company for the purchase of land had been [paid] back with interest in the year 2011. It is alleged that the Company was actually paid back by [illegible] RHC Holding over a [illegible]

(b) During year ended March 31, 2018, the Registrar of Companies (ROC) under section 206(1) of the Companies Act, 2013, *inter alia*, had also sought information in relation to the Company. All requisite information in this regard has been duly shared by the Company with the ROC.

with Special Leave Petition which has also been filed by HHPL for *inter alia* challenging the actions of State Government, City Industrial Development Corporation and NMMC which led to the passing of the said Termination Order. The Hon'ble Supreme Court of India in the hearing held on January 30, 2017 ordered "Status Quo'. SLP has been admitted on January 22, 2018 and "Status Quo" has been continuing. Based on external legal counsel opinion, management is confident that HHPL is in compliance of conditions of Hospital Lease Agreement and accordingly considers that no adjustment is required to the unaudited Consolidated Financial Results

9. Corporate Social Responsibility (CSR) activities of the company and its subsidiaries during earlier years were carried out through Fortis Charitable Foundation (FCF) (erstwhile promoter entity) with whom dealings have been stopped.

FORTIS HEALTHCARE LIMITED
CIN: L85110PB1996PLC045933
Fortis Hospital, Sector 62 Phase – VIII, Mohali - 160062
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

Court has observed that prima facie, it appears to be acquisition of proprietary interest to subserve the business structure of the Company, as suggested by IHH/NTK while observing that it is a matter to be enquired into and facts to be assessed in light of any forensic analysis, if the court so deems appropriate.

Pursuant to the Judgement, Hon'ble High Court of Delhi vide its order dated 18th October 2022 has directed Decree Holder

ended March 31, 2021, in view of the aforesaid suo moto contempt notice, for abundant caution, an ... application was filed by the Company before
the Hon'ble Supreme Court of India, praying for grant of permission to it and ... its subsidiaries for changing their respective names
... ds and logos, and for continued usage of the same if the said

FORTIS HEALTHCARE LIMITED

EARNINGS PRESENTATION– Q3 FY23 & 9M FY23


TUESDAY
1
8
13
21
28
27









Q2FY23 & Q3FY23 includes exceptional gain of INR 51.6 Cr & INR 11.5 Cr, respectively, which pertains to reversal of impairment in an associate Company















Fortis



Fortis

Fortis

TM















Fortis


















Fortis

	9M FY22	9M FY23

Press Release

February 10, 2023

Fortis Healthcare reports Q3 FY23 Financial Results

Consolidated Revenues at INR 1,560 Crs; EBITDA at INR 288 Crs, 18.5% margin

Hospital business revenues up 13.3% to INR 1,267 Crs in Q3
EBITDA at INR 217 Crs; 17.1% margin.
Hospital business ARPOB increases 8.4% to INR 2.02 Crs

Adjusted for covid revenues, diagnostic business revenues grow 7% vs Q3 FY22

Net Debt to EBITDA at 0.41x against 0.53x in corr. previous period

- **PBT prior to exceptional items at INR 174.6 Crs versus INR 184.5 Crs in Q3 FY22**
- **PAT at INR 142.1 Crs versus INR 141.7 Crs in Q3FY22**
- **Consolidated performance in Q3 reflects the increasing contribution from the hospital business offsetting the impact witnessed in the diagnostics business as a result of the decline in covid volumes versus Q3 FY22.**

Consolidated Financial Snapshot

Particulars ***(INR Crs)***	**Q3FY23**	**Q3FY22**	**% Change YoY**	**YTD Nine Months FY23**	**YTD Nine Months FY22**	**% Change YoY**
Revenue - Hospitals	1,267.4	1,118.2	13.3%	3,756.8	3,223.3	16.6%
- Diagnostics *(net)*	292.4	348.4	(11.0%)	898.1	1,116.2	(19.5%)
Consolidated	**1,599.9**	**1,466.7**	**6.4%**	**4,654.9**	**4,339.5**	**7.3%**
EBITDA - Hospitals^	217.0	190.2	14.1%	670.5	528.9	30.8%
- Diagnostics	71.1	103.4	(31.2%)	207.9	341.6	(39.1%)
Consolidated	**288.1**	**293.6**	**(1.9%)**	**878.4**	**869.1**	**1.1%**
EBITDA Margin - Hospitals	17,1%	17.0%		17.8%	16.4%	
- Diagnostics	24.3%	29.7%		23.2%	30.5%	
Consolidated	**18.5%**	**20.0%**		**18.9%**	**20.0%**	

Profit Before Tax *(Before exceptional item)*	174.6	184.5	(5.4%)	567.2	546.5	3.8%

Press Release

February 10, 2023

Profit After Tax ***(Before exceptional item)***	**130.7**	**133.3**	**(2.0%)**	**431.6**	**388.1**	**11.2%**
Reported Profit After Tax*	142.1	141.7	0.3%	494.7	702.9	(29.6%)
Reported Profit After Tax after Minority Interest and Share in Associates *	129.6	116.7	11.0%	456.2	487.2	(6.4%)
Earnings per share (EPS)	1.72	1.55	11.0%	6.04	6.45	(6.4%)

** Includes an exceptional gain of INR 315 Crs for 9M FY22 on remeasurement of the previously held equity interest of SRL in the SRL-DDRC JV at its fair value post acquisition of the balance 50% stake in the said JV in April 2021. 9MFY23 includes an exceptional gain of INR 63 Cr which primarily pertains to reversal of impairment in an associate Company.*

^ Excludes dividend income received during 9MFY23 from the Company's majority owed (57%) subsidiary SRL Limited as a result of inter-company elimination. Hospital business 9MFY23 reported EBITDA with dividend income was INR 692 Crs.

Gurugram, February 10, 2023: , -0amongst leading healthcare delivery companies, today announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2022.

- Q3FY23 hospital business revenues were at INR 1,267.4 Crs versus INR 1,118.2 Crs in Q3FY22 and INR 1,297 Crs in Q2FY23.

- Hospital business revenues increased 13.3% versus the corresponding previous quarter, led by an 8.4% increase in ARPOB to INR 2.02 Crs, better occupancy and a 73% increase in international patient revenues versus the corresponding previous quarter.

- Occupancy and ARPOB were higher versus Q3 FY22.

KPIs	***Q3 FY23***	***Q3 FY22***	***YTD Nine Months FY23***	***YTD Nine Months FY22***
Occupancy	*66.1%*	*65.4%*	*67.0%*	*65.0%*
ARPOB (INR Cr)	*2.02*	*1.86*	*1.97*	*1.77*
ALOS (Days)	*3.77*	*3.52*	*3.70*	*3.79*

- Q3 FY23 diagnostics business gross revenues stood at INR 331.5 Crs versus INR 388.5 Crs in Q3 FY22, primarily impacted by lower covid volumes (including covid allied test volumes). Revenues for the quarter (excluding covid and covid allied tests) stood at INR 321 Crs versus INR 300 Crs for Q3FY22 and INR 329 Crs in Q2 FY23.

- Net debt to EBITDA was at 0.41 vs 0.53 (basis annualized EBITDA of Q3 FY23 and Q3 FY 22, respectively). Net debt was at INR 471 Crs as on December 31, 2022 versus INR 549 Crs as on March 31, 2022 and INR 621 Cr as on December 31, 2021.

Press Release

February 10, 2023

HOSPITAL BUSINESS HIGHLIGHTS

- The revenue contribution from the Oncology, Orthopaedics, Renal Sciences, Cardiac Sciences, Neurosciences and Gastroenterology grew 15.8% YoY. Their contribution to overall hospital revenues increased to 60.9% in Q3 FY23 from 59.3% in Q3 FY22.

- Revenues from Oncology grew 39.3% and contributed 14% to overall hospital revenues as compared to 11% in the corresponding previous period.

- Many of the C facilities i.e. FMRI, Shalimar Bagh, Anandpur, Amritsar and Kalyan performed better in revenues both versus the corresponding and trailing quarter.

- Q3 continued to witness an uptick in international patient revenues which stood at INR 114 Crs, a growth of 73% over Q3 FY22 and also better than Q2 FY23. International patient revenue contribution increased to 9.0% of hospital revenues versus 5.9% and 8.4% in Q3 FY22 and Q2 FY23 respectively.

- Revenues from digital channels such as websites, My Fortis app and online campaigns increased 12% over Q3 FY22 and their contribution to overall hospital revenues was at 22.6% versus 22.9% in Q2 FY23.

- During the quarter, the Company onboarded eminent clinicians in the medical specialties of Medical and Surgical Oncology, Pediatric Cardiology and Orthopedics.

- The Company commenced its EMR (Electronic Medical Records) implementation project. EMR implementation is expected to significantly enhance patient care allowing quick access to healthcare records and faster diagnosis and treatment. This would be rolled out across the Fortis network in a phased manner when developed and ready.

DIAGNOSTICS BUSINESS HIGHLIGHTS

During Q3FY23, SRL conducted approx. 9.37 Mn tests compared to 9.97 mn tests in the trailing quarter and versus 11.25 Mn tests in Q3FY22.

Non covid revenues (excluding Covid and Covid allied tests) grew 7.0% versus Q3FY22. The overall diagnostics revenues declined primarily due to lower covid volumes as compared to Q3 FY22 which witnessed a severe Covid wave. For 9M FY23, non-covid revenues grew by 12% versus the corresponding previous period.

, -covid) increased to 33% from 30% in Q3 FY22.

Press Release

February 10, 2023

[redacted]

Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, Our Q3 results reflect the steady

our hospital business is growing from strength to strength and today contributes to more than 75% of our overall earnings (EBITDA). It is also pertinent to highlight that the hospital performance has by and large offset the decline we have seen in the diagnostics business primarily as a result of the decline in covid volumes. Revenues from our key medical specialties are gaining traction complimented by our focus on continuing to onboard quality medical talent. Investments in bed expansion in facilities such as Mulund and BG road and in medical equipment such as Linac and MRI 3T machines are on track. We have embarked on a significant initiative in our Digital Transformation journey by commissioning the development of an Electronic Medical Record (MR) system pan-Fortis. This would enable us to streamline information flow, increase accessibility to healthcare records and provide a superior patient experience which has been our constant focus.

Commenting on the results for the quarter, Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, Q3 has witnessed a healthy set of earnings for the Company with consolidated revenues at INR 1,560 Crs and margins of 18.5%. Our hospital business has recorded an ARPOB of INR 2.02 Crs, a growth of 8.4%; with occupancy levels slightly better than the corresponding previous quarter at 66%. More importantly, most of our key specialties have done well with Oncology, Gastroenterology, Orthopedics and Renal Sciences contributing significantly to overall hospital revenues and growing 39%, 24%, 21% and 21% respectively. Our diagnostics business0 performance was impacted by the decline in covid volumes. Non covid revenues however grew 7% for the quarter and 12% for 9MFY23 versus the corresponding previous periods. The business is now showing initial signs of stabilization in the aftermath of the covid surge and the challenging industry environment. SRL continues to focus on improving its channel mix and adding to its specialized test menu such as those in the area of genomics. In parallel, it continues to optimize its network and customer touch point to lab metrics in order to improve utilization.

Press Release

February 10, 2023

About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates 27 healthcare facilities (including JVs and O&M facilities). The Company network comprises approximately 4,300 operational beds and 400 diagnostics centres.

For further details please contact:

Anurag Kalra / Gaurav Chugh
Investor Relations
+91-9810109253 / 9958588900
Fortis Healthcare Limited

Ajey Maharaj
Corporate Communication
+91-9871798573
Fortis Healthcare Limited